Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain
the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in
Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles
and JavaScript.
Race to the clinic reignites for an off-the-shelf alternative to autologous CAR-T cell therapy, even as concerns over chromosomal abnormalities linger.
Sanatech Seed’s Sicilian Rouge CRISPR-edited ‘health-promoting’ tomatoes reach consumers and may open the market to more genome-edited fruit, vegetables and even fish.
Peptide jabs targeting T cells could be especially useful for people with compromised immune systems, as backups for spike-based vaccines, or against Omicron and other emerging variants.
Promising clinical data for two small molecules targeting SARS-CoV-2 usher in era of antiviral drug that can be taken in outpatient and low-income settings.
India’s approval of a nucleic acid vaccine hints at a solution for low-income nations—if the limitations of current delivery technology can be overcome.
Lab-grown fish taste the same as their wild and farmed counterparts, offering an alternative to traditional seafood. But will it ever make economic sense to produce this kind of protein?
Life scientists are preparing to test quantum computers for applications beyond computational chemistry, such as selecting responders to cancer therapies.
Early results promise a one-off treatment, but gene-editing and gene therapies will have to show durable protection and be affordable to the many patients with sickle cell disease in the world.
Scientists are using new tools to mine the non-coding part of the genome, known as ‘dark matter’, to uncover disease-linked changes in promoters, silencers and enhancers for target discovery.
The milestone approval for Amgen’s drug Lumakras will galvanize targeted therapy efforts against Ras oncoproteins and provides a powerful new last line of defense for patients with lung cancer.
Chinese upstart companies and IT goliaths hope to turn country’s artificial intelligence prowess into world-leading drug innovation. Do they have an edge over Western players?
Companies are designing next-generation antibodies modeled on those taken from unique individuals whose immune systems can neutralize any COVID-19 variant—and related coronaviruses, too.
With late-stage trial success, venture funding and next-generation alpha emitters on the way, targeted radiotherapy drugs are finally “getting the attention they deserve.”
Researchers hope that antisense oligo clinical trial failures in Huntington’s will shed light on mechanism and drug biodistribution and galvanize ongoing drug development efforts.